Clinical trial NCT00241462: Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
Official title: Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Breast Cancer
Keywords: Advanced Breast Cancer
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-10-19
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.


Eligibility criteria: Inclusion Criteria:

* Postmenopausal
* Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
* Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment

Exclusion Criteria:

* Life threatening metastases

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Alkmaar
country: Netherlands
facility: Research Site
city: Almelo
country: Netherlands
facility: Research Site
city: Almere
country: Netherlands
facility: Research Site
city: Amsterdam
country: Netherlands
facility: Research Site
city: Apeldoorn
country: Netherlands
facility: Research Site
city: Assen
country: Netherlands
facility: Research Site
city: Bergen op Zoom
country: Netherlands
facility: Research Site
city: Capelle Aan Den Ijssel
country: Netherlands
facility: Research Site
city: Delft
country: Netherlands
facility: Research Site
city: Delfzijl
country: Netherlands
facility: Research Site
city: Doetinchem
country: Netherlands
facility: Research Site
city: Dokkum
country: Netherlands
facility: Research Site
city: Dordrecht
country: Netherlands
facility: Research Site
city: Drachten
country: Netherlands
facility: Research Site
city: Ede Gld
country: Netherlands
facility: Research Site
city: Eindhoven
country: Netherlands
facility: Research Site
city: Geldrop
country: Netherlands
facility: Research Site
city: Gorinchem
country: Netherlands
facility: Research Site
city: Hardenberg
country: Netherlands
facility: Research Site
city: Heerenveen
country: Netherlands
facility: Research Site
city: Heerlen
country: Netherlands
facility: Research Site
city: Hellevoetsluis
country: Netherlands
facility: Research Site
city: Hilversum
country: Netherlands
facility: Research Site
city: Hoogeveen
country: Netherlands
facility: Research Site
city: Leiden
country: Netherlands
facility: Research Site
city: Leiderdorp
country: Netherlands
facility: Research Site
city: Leidschendam
country: Netherlands
facility: Research Site
city: Meppel
country: Netherlands
facility: Research Site
city: Nieuwegein
country: Netherlands
facility: Research Site
city: Oss
country: Netherlands
facility: Research Site
city: Roermond
country: Netherlands
facility: Research Site
city: Rotterdam
country: Netherlands
facility: Research Site
city: S-Gravenhage
country: Netherlands
facility: Research Site
city: Stadskanaal
country: Netherlands
facility: Research Site
city: Terneuzen
country: Netherlands
facility: Research Site
city: Tilburg
country: Netherlands
facility: Research Site
city: Utrecht
country: Netherlands
facility: Research Site
city: Vlaardingen
country: Netherlands
facility: Research Site
city: Winschoten
country: Netherlands
facility: Research Site
city: Winterswijk
country: Netherlands
facility: Research Site
city: Zeist
country: Netherlands
facility: Research Site
city: Zevenaar
country: Netherlands
facility: Research Site
city: Zwolle
country: Netherlands
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: AstraZeneca Netherlands Medical Director, MD
role: STUDY_DIRECTOR
References: